| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7132416 | IPSEN | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia |
Sep, 2022
(1 year, 8 months ago) | |
| US10975046 | IPSEN | Crystal modifications of odevixibat |
Jun, 2039
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10011633 | IPSEN | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(7 years from now) | |
| US10093697 | IPSEN | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(7 years from now) | |
| US9694018 | IPSEN | IBAT inhibitors for the treatment of liver disease |
Nov, 2031
(7 years from now) | |
| US11732006 | IPSEN | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(7 years from now) | |
| US10981952 | IPSEN | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(7 years from now) | |
| US10487111 | IPSEN | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(7 years from now) | |
| US11802115 | IPSEN | Pharmaceutical formulation of odevixibat |
Jun, 2039
(15 years from now) | |
| US11801226 | IPSEN | Pharmaceutical formulation of odevixibat |
Jun, 2039
(15 years from now) | |
| US11365182 | IPSEN | Crystal modifications of odevixibat |
Jun, 2039
(15 years from now) | |
| US11583539 | IPSEN | Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors |
Nov, 2041
(17 years from now) | |
Bylvay is owned by Ipsen.
Bylvay contains Odevixibat.
Bylvay has a total of 12 drug patents out of which 1 drug patent has expired.
Expired drug patents of Bylvay are:
- US7132416
Bylvay was authorised for market use on 20 July, 2021.
Bylvay is available in capsule;oral, capsule, pellets;oral dosage forms.
Bylvay can be used as method of treating pruritus in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic), method of reducing serum bile acids in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic), method of reducing serum bile acids in patients 12 months or older suffering from alagille syndrome (algs), method of treating cholestatic pruritus in patients 12 months or older suffering from alagille syndrome (algs).
Drug patent challenges can be filed against Bylvay from 20 July, 2025.
The generics of Bylvay are possible to be released after 12 November, 2041.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2026 |
| Orphan Drug Exclusivity(ODE-436) | Jun 13, 2030 |
| New Indication(I-918) | Jun 13, 2026 |
| Orphan Drug Exclusivity(ODE-363) | Jul 20, 2028 |
Drugs and Companies using ODEVIXIBAT ingredient
NCE-1 date: 20 July, 2025
Market Authorisation Date: 20 July, 2021
Treatment: Method of reducing serum bile acids in patients 12 months or older suffering from alagille syndrome (algs); Method of treating pruritus in patients 3 months or older suffering from progressive familia...
Dosage: CAPSULE, PELLETS;ORAL; CAPSULE;ORAL
BYLVAY family patents
